Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.18
+$0.04 · +0.97%
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Latest quote
$4.18
+$0.04 · +0.97%
After-hours
$4.18
$0.00 · 0.00%
Oct 8, 4:15 PM ET
Regular session · ET · Market data may be delayed.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Day range
Current $4.18
52-week range
Current $4.18
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
73
Undervalued
Sentiment
42
Mixed
Risk
69
High Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Day range
Current $4.18
52-week range
Current $4.18
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 35.58M USD | 7.57M USD | 5.12M USD | 9.03M USD | 12M USD |
| Cost of goods sold | 3.44M USD | 2.74M USD | 746K USD | 725K USD | 472K USD |
| Gross profit | 32.14M USD | 4.83M USD | 4.38M USD | 8.31M USD | 11.53M USD |
| Research and development | 8.86M USD | 11.84M USD | 20.3M USD | 12.2M USD | 15.93M USD |
| Selling, general, and administrative | 35.22M USD | 58.82M USD | 47.31M USD | 17.41M USD | 26.98M USD |
| Operating expenses | 44.08M USD | 70.75M USD | 70.14M USD | 29.6M USD | 42.44M USD |
| Interest income | 929K USD | 1.42M USD | 2.74M USD | 476K USD | 123K USD |
| Interest expense | 7.74M USD | 9.41M USD | 3.96M USD | 2.17M USD | 4.3M USD |
| Depreciation and amortization | 781K USD | 1.27M USD | 836K USD | 718K USD | 472K USD |
| Operating income | −11.94M USD | −65.92M USD | −65.76M USD | −21.3M USD | −30.91M USD |
| Net income | −17.89M USD | −76.58M USD | −67M USD | −24.49M USD | −35.08M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$9.00
115.31% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jul 25, 2025 | 1:10 | — | — |
Effective Jul 25, 2025
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Avantis Total Equity Markets ETF 1AVTMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
